Table 2.
Effect of treatment on mortality in patients with Parkinson’s disease: age and diagnosis subgroup analysis
| Group | No of deaths | Mortality ratio (95% CI)
|
|
|---|---|---|---|
| Age and sex adjusted | Fully adjusted* | ||
| Age 35-59 years | |||
| Levodopa | 5 | 1 | 1 |
| Selegiline | 0 | — | — |
| Selegiline plus levodopa | 0 | — | — |
| Age 60-69 | |||
| Levodopa | 36 | 1 | 1 |
| Selegiline | 11 | 1.68 | 1.88 (0.95 to 3.68) |
| Selegiline plus levodopa | 23 | 0.88 | 0.99 (0.58 to 1.67) |
| Age 70-79 | |||
| Levodopa | 343 | 1 | 1 |
| Selegiline | 61 | 1.49 | 1.49 (1.13 to 1.97) |
| Selegiline plus levodopa | 185 | 1.19 | 1.21 (1.01 to 1.45) |
| Age 80-89 | |||
| Levodopa | 740 | 1 | 1 |
| Selegiline | 64 | 0.89 | 0.90 (0.70 to 1.17) |
| Selegiline plus levodopa | 252 | 1.12 | 1.07 (0.92 to 1.23) |
| No recorded diagnosis of Parkinson’s disease | |||
| Levodopa | 187 | 1 | 1 |
| Selegiline | 16 | 0.60 | 0.58 (0.34 to 0.97) |
| Selegiline plus levodopa | 35 | 1.19 | 1.11 (0.77 to 1.61) |
| Recorded diagnosis of Parkinson’s disease | |||
| Levodopa | 937 | 1 | 1 |
| Selegiline | 120 | 1.25 | 1.30 (1.07 to 1.58) |
| Selegiline plus levodopa | 425 | 1.15 | 1.11 (0.98 to 1.24) |
*
Adjusted for age (for Parkinsonism diagnosis subgroups), sex, use of antidepressants (specifically tricyclics and serotonin reuptake inhibitors), history of cerebrovascular disease and ischaemic heart disease, smoking habit, regional health authority, Parkinsonism diagnosis group (for age subgroups), prevalent or incident case.